Cited by 391PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 551 of the 559 references it cites were found in a registry or an index.

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Open access

Curtin, Nicola J., Szabo, Csaba·2013·Molecular Aspects of Medicine

DOI 10.1016/j.mam.2013.01.006PMC PMC3657315

Open this paper in CoChat — free account

Abstract

The aim of this article is to describe the current and potential clinical translation of pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first section of the present review summarizes the available preclinical and clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer. HRR defects are classically associated with BRCA1 and 2 mutations associated with familial breast and ovarian cancer, but there may be many other causes of HRR defects. Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects. Multiple lines of preclinical data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation. Both single agent and combination clinical trials are underway. The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clinical development. The second section of the present review summarizes the role of PARP in selected non-oncologic indications. In a number of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clinical translatability of PARP inhibition is supported by multiple lines of preclinical data, as well as observational data demonstrating PARP activation in human tissue samples. In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathology. Accordingly, multiple lines of preclinical data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses. As the clinical trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clinical investigations, aimed at testing of PARP inhibitors for various non-oncologic indications, will be initiated, as well.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.mam.2013.01.006

Cites

551 of 551 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation
Cuzzocrea, S., Zingarelli, B., Gilad, E., Hake, P. W., Salzman, A. L., & Szabó, C. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01417-9 · Cited by 85
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Self-citation
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Heart-Lung Transplantation
Yarbrough, W. M., Robbins, R. C., & Mallidi, H. R. (2016) · CRC Press eBooks · doi:10.3109/9781439802571-25 · Cited by 2,161
Peroxynitrite: biochemistry, pathophysiology and development of therapeutics
Szabó, C., Ischiropoulos, H., & Radi, R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2222 · Cited by 2,134
Self-citation

Flagged first, then by citations

Show all 559 references

8 of the 559 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Du, 2007, Local administration of the poly (ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice, J. Neurotrauma, 24, 1399, 10.1089/neu.2007.0305 · DOI
Komjáti, 2005, Poly(ADP-ribose) polymerase inhibitors as therapeutic agents for stroke and brain trauma. Current Drug Targets, CNS Neurol. Disord., 4, 179
Miknyoczki, 2003, Chemopotentiation of temozlomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor, Mol. Cancer Ther., 2, 371

Sorted by citations

Items 101–200 of 391

Towards small molecule inhibitors of mono-ADP-ribosyltransferases
Ekblad, T., Lindgren, A. E. G., Andersson, C. D., Caraballo, R., Thorsell, A. G., Karlberg, T., Spjut, S., Linusson, A., Schuler, H., & Elofsson, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.067 · Cited by 49
Regulated Cell Death Seen through the Lens of Islet Transplantation
Bruni, A. D. C., Bornstein, S. R., Linkermann, A., & Shapiro, A. M. J. (2018) · Cell Transplantation · doi:10.1177/0963689718766323 · Cited by 48
Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods
Gan, N., Sun, Q., Tang, P., Wu, D., Xie, T., Zhang, Y., & Li, H. (2018) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2018.07.100 · Cited by 48
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Zhang, J., Gao, Y., Zhang, Z., Zhao, J., Jia, W., Xia, C., Wang, F., & Liu, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01352 · Cited by 49
PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA receptors
Gerace, E., Masi, A., Resta, F., Felici, R., Landucci, E., Mello, T., Pellegrini-Giampietro, D. E., Mannaioni, G., & Moroni, F. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.023 · Cited by 45
The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity
Chen, S.-M., Chou, W., Hu, L., Hsiung, C.-N., Chu, H., Huang, Y.-L., Hsu, H.-M., Yu, J.-C., & Shen, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128472 · Cited by 46
PARPing for balance in the homeostasis of poly(ADP-ribosyl)ation
Schuhwerk, H., Atteya, R., Siniuk, K., & Wang, Z. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.011 · Cited by 47
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M. L., Kaufman, B., Robson, M. E., Telli, M. L., Dieras, V. C., Han, H. S., Garber, J. E., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0412 · Cited by 45
Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty
Ruan, Q., Ruan, J., Zhang, W., Qian, F., & Yu, Z. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.010 · Cited by 44
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia
Lee, T. W., Wong, W. W., Dickson, B. D., Lipert, B. A., Cheng, G. J., Hunter, F. W., Hay, M. P., & Wilson, W. R. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1664787 · Cited by 46
Imaging the DNA damage response with PET and SPECT
Knight, J. C., Koustoulidou, S., & Cornelissen, B. T. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3604-1 · Cited by 44
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study
Landrum, L. M., Brady, W. E., Armstrong, D. K., Moore, K. N., DiSilvestro, P., O’Malley, D. M., Tenney, M. E., Rose, P. G., & Fracasso, P. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.024 · Cited by 42
Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo
Thomas, C. J., Ji, Y., Lodhi, N., Kotova, E., Pinnola, A. D., Golovine, K. V., Makhov, P. B., Pechenkina, K., Kolenko, V. M., & Tulin, A. V. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.001 · Cited by 41
The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third‐degree burn injury
Ahmad, A., Oláh, G., Herndon, D. N., & Szabó, C. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13735 · Cited by 41
Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?
Coco, C., Sgarra, L., Potenza, M. A., Nacci, C., Pasculli, B., Barbano, R., Parrella, P., & Montagnani, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122949 · Cited by 46
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers
Mesquita, K. A., Alabdullah, M., Griffin, M., Toss, M. S., Fatah, T. M. A. A., Alblihy, A., Moseley, P. M., Chan, S. Y. T., Rakha, E. A., & Madhusudan, S. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.02.014 · Cited by 40
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences
Mangerich, A., Dębiak, M., Birtel, M., Ponath, V., Balszuweit, F., Lex, K., Martello, R., Burckhardt-Boer, W., Strobelt, R., Siegert, M., et al. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.09.010 · Cited by 42
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
Badawy, A. A. ‐. (2020) · Bioscience Reports · doi:10.1042/bsr20202856 · Cited by 39
Regulation of Mitochondrial Poly(ADP-Ribose) Polymerase Activation by the β-Adrenoceptor/cAMP/Protein Kinase A Axis during Oxidative Stress
Brunyánszki, A., Oláh, G., Coletta, C., Szczęsny, B., & Szabó, C. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094318 · Cited by 39
Human DNA Ligases: A Comprehensive New Look for Cancer Therapy
Singh, D. K., Krishna, S., Chandra, S., Shameem, M., Deshmukh, A. L., & Banerjee, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21298 · Cited by 37
Modulation of Poly(ADP-Ribose) Polymerase-1 (PARP-1)-Mediated Oxidative Cell Injury by Ring Finger Protein 146 (RNF146) in Cardiac Myocytes
Gerő, D., Szoleczky, P., Chatzianastasiou, A., Papapetropoulos, A., & Szabó, C. (2014) · Molecular Medicine · doi:10.2119/molmed.2014.00102 · Cited by 38
A Study into the ADP-Ribosylome of IFN-γ-Stimulated THP-1 Human Macrophage-like Cells Identifies ARTD8/PARP14 and ARTD9/PARP9 ADP-Ribosylation
Higashi, H., Maejima, T., Lee, L. H., Yamazaki, Y., Hottiger, M. O., Singh, S. A., & Aikawa, M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00895 · Cited by 36
Design, synthesis and anticancer activities evaluation of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units
He, X., Li, X., Liang, J., Cao, C., Li, S., Zhang, T., & Meng, F. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.02.008 · Cited by 36
The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
Alemasova, E. E., Naumenko, K. N., Kurgina, T. A., Anarbaev, R. O., & Lavrik, O. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25158 · Cited by 36
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR
Young, R. J., França, P. D. D. S., Pirovano, G., Piotrowski, A. F., Nicklin, P. J., Riedl, C. C., Schwartz, J., Bale, T., Donabedian, P. L., Kossatz, S., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa119 · Cited by 35
Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke
Charriaut‐Marlangue, C., Leconte, C., Csaba, Z., Chafa, L., Pansiot, J., Talatizi, M., Simon, K., Moretti, R., Marchand‐Leroux, C., Baud, O., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.05.022 · Cited by 35
Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS
Li, D., Kou, Y., Gao, Y., Liu, S., Yang, P., Hasegawa, T., Su, R., Guo, J., & Li, M. (2021) · Aging · doi:10.18632/aging.202386 · Cited by 34
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics
Rabenau, K. E., & Hofstatter, E. W. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.006 · Cited by 34
Poly(ADP-Ribose) polymerase 1 as a key regulator of DNA repair
Khodyreva, S. N., & Lavrik, O. I. (2016) · Molecular Biology · doi:10.1134/s0026893316040038 · Cited by 34
Analyzing structure–function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLaPARP1knock-out cells
Rank, L., Veith, S., Gwosch, E., Demgenski, J., Ganz, M., Jongmans, M. C. J., Vogel, C., Fischbach, A., Buerger, S., Fischer, J. M. F., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw859 · Cited by 36
Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities
Chen, J., Li, X., Xu, S., Zhang, M., Wu, Z., Zhang, X., Xu, Y., & Chen, Y. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00077 · Cited by 34
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Xie, Y., Xiao, D., Li, D., Peng, M., Peng, W., Duan, H., & Yang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441222 · Cited by 35
Functional aspects of PARylation in induced and programmed DNA repair processes: Preserving genome integrity and modulating physiological events
Robert, I., Karicheva, O., Reina‐San‐Martin, B., Schreiber, V., & Dantzer, F. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.02.001 · Cited by 40
Recent advances in the targeting of human DNA ligase I as a potential new strategy for cancer treatment
Saquib, M., Ansari, M. I., Johnson, C. R., Khatoon, S., Hussain, M. K., & Coop, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111657 · Cited by 32
Targeting Nuclear NAD+ Synthesis Inhibits DNA Repair, Impairs Metabolic Adaptation and Increases Chemosensitivity of U-2OS Osteosarcoma Cells
Kiss, A., Ráduly, A. P., Regdon, Z., Polgár, Z., Tarapcsák, S., Sturniolo, I., El‐Hamoly, T., Virág, L., & Hegedűs, C. (2020) · Cancers · doi:10.3390/cancers12051180 · Cited by 32
Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers
Labay, E., Mauceri, H. J., Efimova, E. V., Flor, A. C., Sutton, H. G., Kron, S. J., & Weichselbaum, R. R. (2016) · Oncotarget · doi:10.18632/oncotarget.8984 · Cited by 33
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
Noll, A., Illuzzi, G., Amé, J., Dantzer, F., & Schreiber, V. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0333-2 · Cited by 31
Poly( ADP ‐ribose) polymerase inhibition with HYDAMTIQ reduces allergen‐induced asthma‐like reaction, bronchial hyper‐reactivity and airway remodelling
Lucarini, L., Pini, A., Gerace, E., Pellicciari, R., Masini, E., & Moroni, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12197 · Cited by 31
Therapeutic potential of nicotinamide adenine dinucleotide (NAD)
Arenas‐Jal, M., Suñé-Negre, J. M., & García‐Montoya, E. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173158 · Cited by 30
Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
Kim, H., Choi, J., & Lee, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051130 · Cited by 30
Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review
Xiong, J., Barayan, R., Louie, A. V., & Lok, B. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.008 · Cited by 31
Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo
Janzen, D. M., Paik, D. Y., Rosales, M. A., Yep, B., Cheng, D., Witte, O. N., Kayadibi, H., Ryan, C. M., Jung, M. E., Faull, K. F., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0572 · Cited by 29
Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting
Cass, Y., Connor, T. H., & Tabachnik, A. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216637217 · Cited by 30
Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats
Korkmaz‐Icöz, S., Szczęsny, B., Marcatti, M., Li, S., Ruppert, M., Lasitschka, F., Loganathan, S., Szabó, C., & Szabo, G. B. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13983 · Cited by 30
Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy
Xin, J., Zhang, K., Huang, J., Luo, X., Gong, X., Yang, Z., Lin, H., Shan, H., & Gao, J. (2018) · Biomaterials Science · doi:10.1039/c8bm01039k · Cited by 29
Nanotechnology-mediated delivery of resveratrol as promising strategy to improve therapeutic efficacy in triple negative breast cancer (TNBC): progress and promises
Ahmad, J., Ahamad, J., Algahtani, M. S., Garg, A., Shahzad, N., Ahmad, M. Z., & Imam, S. S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2317194 · Cited by 29
Identification of hub genes and small-molecule compounds related to intracerebral hemorrhage with bioinformatics analysis
Liu, Z., Zhang, R., Chen, X., Yao, P., Yan, T., Liu, W., Yao, J., Sokhatskii, A., Фанилевич, Г. И., & Zhao, S. (2019) · PeerJ · doi:10.7717/peerj.7782 · Cited by 28
Tilianin-loaded Reactive Oxygen Species-Scavenging Nano-Micelles Protect H9c2 Cardiomyocyte Against Hypoxia/Reoxygenation-Induced Injury
Wang, Y., Wang, Y., Wang, X., & Hu, P. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000587 · Cited by 29
Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies
Zou, J., Lin, J.-F., Li, C., Zhao, R., Fan, L., Yu, J., & Shao, J. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666181016145940 · Cited by 28
50Years of poly(ADP-ribosyl)ation
Virág, L. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.05.002 · Cited by 27
Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor
Krainz, T., Lamade, A. M., Du, L., Maskrey, T. S., Calderon, M. J., Watkins, S. C., Epperly, M. W., Greenberger, J. S., Bayır, H., Wipf, P., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00423 · Cited by 27
Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins
Manasaryan, G., Suplatov, D. A., Pushkarev, S. V., Drobot, V., Kuimov, A. N., Švedas, V. K., & Nilov, D. K. (2021) · Cancers · doi:10.3390/cancers13061201 · Cited by 27
“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Incorvaia, L., Passiglia, F., Rizzo, S., Galvano, A., Listì, A., Barraco, N., Maragliano, R., Calò, V., Natoli, C., Ciaccio, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14409 · Cited by 26
Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging
Vinegoni, C., Feruglio, P. F., Brand, C., Lee, S., Nibbs, A. E., Stapleton, S., Shah, S., Gryczyński, I., Reiner, T., Mazitschek, R., et al. (2017) · Nature Protocols · doi:10.1038/nprot.2017.043 · Cited by 26
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
Shah, G. M., Robu, M., Purohit, N. K., Rajawat, J., Tentori, L., & Graziani, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00279 · Cited by 25
PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
Hsu, W.-J., Chen, C., Chang, Y., Cheng, C., Tsai, Y.-H., & Lin, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101009 · Cited by 25
DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication
Arena, A., Montani, M. S. G., Romeo, M. A., Benedetti, R., Gaeta, A., & Cirone, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119168 · Cited by 25
New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
Zhan, S., Yung, M. M. H., Siu, M. K. Y., Jiao, P., Ngan, H., Chan, D. W., & Chan, K. K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315263 · Cited by 28
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation
Xie, Z., Zhou, Y., Zhao, W., Jiao, H., Chen, Y., Yang, Y. G., & Li, Z. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.060 · Cited by 25
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy
Chen, W., Guo, N., Qi, M., Dai, H., Hong, M., Guan, L., Huan, X., Song, S., He, J., Wang, Y.-Q., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.053 · Cited by 26
DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
Reuvers, T. G. A., Verkaik, N. S., Stuurman, D. C., de Ridder, C., Groningen, M. C. C., de Blois, E., & Nonnekens, J. (2023) · Theranostics · doi:10.7150/thno.82963 · Cited by 24
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 25
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases
Shui, I. M., Burcu, M., Shao, C., Chen, C., Liao, C.-Y., Jiang, S., Cristescu, R., & Parikh, R. B. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00764-1 · Cited by 24
PARP inhibitors as antitumor agents: a patent update (2013-2015)
Yuan, Z., Chen, J., Li, W., Li, D., Chen, C., Gao, C., & Jiang, Y. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1259413 · Cited by 24
Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach
Baptista, S. J., Silva, M. M., Moroni, E., Meli, M., Colombo, G., Dinis, T. C. P., & Salvador, J. A. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170846 · Cited by 24
Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation
Srivastava, P., Sarma, A., & Chaturvedi, C. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190516 · Cited by 24
The Biological Basis of Radiation Oncology
Zeman, E. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00001-0 · Cited by 26
Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation
Wilson, A., Menon, V., Khan, Z., Alam, A., Litovchick, L., & Yakovlev, V. A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101169 · Cited by 24
Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation
Waïssi, W., Nicol, A., Jung, M., Rousseau, M., Jarnet, D., Noël, G., & Burckel, H. (2021) · Cancers · doi:10.3390/cancers13030527 · Cited by 23
Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation
Li, S., Li, X., Zhang, T., Zhu, J., Liu, K.-L., Wang, D.-P., & Meng, F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104840 · Cited by 23
Synthesis and biological evaluation of a tumor-selective degrader of PARP1
Pu, C., Wang, S., Luo, D., Liu, Y., Ma, X., Zhang, H., Yu, S., Lan, S., Huang, Q., Deng, R., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116908 · Cited by 24
PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
Wang, X., Zeng, X., Li, D., Zhu, C., Guo, X., Feng, L., & Yu, Z. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113458 · Cited by 24
Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
Li, J., Li, Q., Zhang, L., Zhang, S., & Dai, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114028 · Cited by 24
Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways
Preyat, N., & Léo, O. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.110 · Cited by 23
Novel PARP inhibitors sensitize human leukemic cells in an endogenous PARP activity dependent manner
Hegde, M. B., Mantelingu, K., Swarup, H. A., Pavankumar, C. S., Qamar, I., Raghavan, S. C., & Rangappa, K. S. (2016) · RSC Advances · doi:10.1039/c5ra19150e · Cited by 23
PCAT-1: A pivotal oncogenic long non-coding RNA in human cancers
Yang, Z., Zhao, S., Zhou, X., Zhao, H., & Jiang, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.014 · Cited by 22
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
Fritz, C. E., Portwood, S. M., Przespolewski, A., & Wang, E. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100696 · Cited by 23
PARP Inhibitors in Prostate Cancer
Grewal, K., Grewal, K., & Tabbara, I. A. (2021) · Anticancer Research · doi:10.21873/anticanres.14807 · Cited by 23
Expression of DNA repair proteins in endometrial cancer predicts disease outcome
Mhawech-Fauceglia, P. Y., Wang, D., Kim, G., Sharifian, M., Chen, X., Liu, Q., Lin, Y. G., Liu, S., & Pejovic, T. B. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.002 · Cited by 22
Mechanisms and potential therapeutic targets in allergic inflammation: recent insights
von Gunten, S., Cortinas-Elizondo, F., Kollárik, M., Beißwenger, C., & Lepper, P. M. (2013) · Allergy · doi:10.1111/all.12312 · Cited by 22
Critical appraisal of MGMT in digestive NET treated with alkylating agents
de Mestier, L., Couvelard, A., Blažević, A., Hentic, O., de Herder, W. W., Rebours, V., Paradis, V., Ruszniewski, P. B., Hofland, L. J., & Cros, J. F. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0227 · Cited by 22
Nickel-Catalyzed Oxidative Decarboxylative Annulation for the Synthesis of Heterocycle-Containing Phenanthridinones
Honeycutt, A. P., & Hoover, J. M. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b03144 · Cited by 21
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
Cropper, J. D., Alimbetov, D. S., Brown, K. T., Likhotvorik, R. I., Robles, A. J., Guerra, J. T., He, B., Chen, Y., Kwon, Y., & Kurmasheva, R. T. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01367-4 · Cited by 21
The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity
Jagetia, G. C., & Reddy, T. K. (2014) · Cited by 21
Synthesis, characterisation and cytotoxic activity of organoruthenium(II)-halido complexes with 1H-benzimidazole-2-carboxylic acid
Pantić, D. N., Aranđelović, S., Radulovic, S. S., Roller, A., Arion, V. B., & Grgurić‐Šipka, S. (2016) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2016.06.024 · Cited by 21
PARP activity and inhibition in fetal and adult oligodendrocyte precursor cells: Effect on cell survival and differentiation
Baldassarro, V. A., Marchesini, A., Giardino, L., & Calzà, L. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.05.011 · Cited by 23
Inhibitors of Poly(ADP-Ribose)Polymerase-1 as Agents Providing Correction of Brain Dysfunctions Induced by Experimental Diabetes
Guzyk, M. M., Dyakun, K., Yanitska, L. V., Pryvrotska, I. B., Krynytska, І., Pishel, I., & Kuchmerovska, T. M. (2017) · Neurophysiology · doi:10.1007/s11062-017-9672-4 · Cited by 20
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
Dickson, B. D., Wong, W. W., Wilson, W. R., & Hay, M. P. (2019) · Molecules · doi:10.3390/molecules24081559 · Cited by 21
Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents
Murai, J., & Pommier, Y. G. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_10 · Cited by 21
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells
Dong, C., Yang, R., Li, H., Ke, K., Luo, C., Yang, F., Shi, X., Zhu, Y., Liu, X., Wong, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-18178-0 · Cited by 21
The romantic history of signaling pathway discovery in cell death: an updated review
Wang, L., Liu, X., Li, Q.-Q., Zhu, Y., Ren, H.-L., Song, J., Zeng, J., Mei, J., Tian, H., Rong, D., et al. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04873-2 · Cited by 22
Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach
Zaffini, R., Gotte, G., & Menegazzi, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s150846 · Cited by 20
Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells
Pavlović, M., Tadić, A., Gligorijević, N., Poljarević, J. M., Petrović, T., Dojčinović, B., Savić, A., Radulovic, S. S., Grgurić‐Šipka, S., & Aranđelović, S. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111155 · Cited by 20
Insights into PARP Inhibitors’ Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays
Papeo, G., Avanzi, N. R., Bettoni, S., Leone, A., Paolucci, M., Perego, R., Quartieri, F., Sirtori, F. R., Thieffine, S., Montagnoli, A., et al. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114538319 · Cited by 20
The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
Kruglov, O., Wu, X., Hwang, S. T., & Akilov, O. E. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002049 · Cited by 19
Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors
Al-Sanea, M. M., Chilingaryan, G., Abelyan, N., Mamikonyan, M., Gasparyan, H. A., Hovhannisyan, S. A., Hamdi, A., Ali, A. R., Selim, S., & Mohamed, A. A. B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272065 · Cited by 19
Poly(ADP-ribosylation) and neurodegenerative disorders
Basello, D. A., & Scovassi, A. I. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.07.005 · Cited by 19
PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells
Ghorai, A., Sarma, A., Chowdhury, P. R., & Ghosh, U. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0703-x · Cited by 19
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
Lester, A., Rapkins, R. W., Nixdorf, S., Khasraw, M., & McDonald, K. L. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1547-4 · Cited by 19
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
McCrudden, C. M., O’Rourke, M., Cherry, K. E., Yuen, H., O’Rourke, D. M., Babur, M., Telfer, B. A., Thomas, H. D., Keane, P. F., Nambirajan, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118187 · Cited by 19
Self-citation

Authors: Curtin, N. J., & Szabo, C.
Affiliations: Newcastle University (GB)
Corresponding author: Curtin, Nicola J.
ORCID: Curtin, Nicola J.
Venue: Molecular Aspects of Medicine
Publisher: Elsevier BV
Published: 2013-12
Volume: 34
Issue: 6
Pages: 1217-1256
ISSN: 0098-2997 (ISSN-L)
DOI: 10.1016/j.mam.2013.01.006
PMC: PMC3657315
OpenAlex: W2017171454
Cited by: 369
References: 559
Citations by year: 2026: 9 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 37 · 2019: 31 · 2018: 26 · 2017: 32 · 2016: 38 · 2015: 50 · 2014: 24 · 2013: 21
FWCI: 4.93
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Molecular Aspects of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institutes of Health
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, poly(ADP-ribose) polymerase, synthetic lethality, homologous recombination deficiency, BRCA mutations, breast cancer, ovarian cancer, temozolomide combination therapy, topoisomerase inhibitors, ionizing radiation, oxidative stress, nitrative stress, necrosis, inflammation, stroke, neurotrauma, shock, acute myocardial infarction, clinical translation
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, Poly(ADP-ribose) Polymerases, Radiation-Sensitizing Agents, Stroke, Translational Research, Biomedical, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks